• Filter By Topic

September 15, 2021

Neuron-specific Mitochondrial Oxidative Stress Results in Epilepsy, Glucose Dysregulation and a Striking Astrocyte Response

Mitochondrial superoxide (O2 ?) production is implicated in aging, neurodegenerative disease, and most recently epilepsy. Yet the specific contribution of neuronal O2 ? to these phenomena is unclear.

September 14, 2021

Knowledge, attitude, and barriers for epilepsy surgery: A survey among resident doctors in a tertiary care center in India

A substantial number of participants lacked the basic knowledge of drug resistant epilepsy and epilepsy surgery. Lack of knowledge was perceived to be the commonest barrier for epilepsy surgery.

September 14, 2021

Knowledge, Attitudes, and Practices of Caregivers of Children with Epilepsy in Sudan

Findings suggest that caregivers require periodic epilepsy-related educational programs. This study is an invaluable tool for tailoring the delivery of information and support resources for caregivers in our region.

September 14, 2021

Insights Into Genes Driving Epilepsy Could Help With Treatment

Danish researchers have found genetic causes for epilepsy in half of children they studied and said half of those could be treated with targeted therapies.

September 14, 2021

Preventing the Long-Term Effects of Traumatic Brain Injury

Understanding how the traumatic brain injury affects the brain, especially in the long term, is a really important gap in research that could help develop new and better treatment options.

September 13, 2021

Epilepsy Research News: September 2021

This month’s research news includes advances in our understanding of the cause of focal cortical dysplasia. This research, conducted by former CURE Epilepsy grantee Dr. Jeong Ho Lee and colleagues, identifies the adenosine signaling pathway as a possible treatment target for this type of epilepsy.   We also report on two studies investigating possible treatments for epilepsy. In the first study, researchers discovered that a cannabis-like chemical naturally found in the brain may be a possible treatment for epilepsy. In the second study, researchers found that a drug  approved for the treatment of multiple sclerosis may be beneficial in the treatment of a rare form of genetic epilepsy.   Summaries of these research discoveries and more are below.  Understanding Focal Cortical Dysplasia: Research from a team of scientists including former CURE Epilepsy grantee Dr. Jeong Ho Lee shows how defects in even a small percentage of cells during fetal development can lead to a type of epilepsy known as focal cortical dysplasia (FCD). Using a mouse model of FCD, the researchers found that mutated neurons were overproducing a protein known as adenosine kinase, leading to a decrease in a substance called adenosine and eventually increased excitability in nearby neurons. "While we need to further investigate the relationship between the concentration of adenosine and the increased excitation of neurons, our results support the medical use of drugs to activate adenosine signaling as a possible treatment pathway for FCD," Professor Lee said.  Following up on this line of research, CURE Epilepsy is currently funding the work of Dr. Detlev Boison and his colleagues to develop an adenosine kinase inhibitor drug as a potential transformative treatment to prevent the development of epilepsy. Learn More  Treating Seizures with Cannabis-Like Chemical: Using advanced imaging techniques in mice, researchers have found that a substance naturally found in the brain, which acts similarly to the main chemical found in cannabis, may lead to a possible treatment for epilepsy. This substance called 2-arachidonoylglycerol, or 2-AG, has the beneficial effect of decreasing seizure activity. However, researchers also found that the rapid breakdown of 2-AG which occurs in the brain initiates a cascade of events that result in the disorientation and amnesia that may follow an epileptic seizure. The researchers note that further study could guide the development of drugs that reduce seizures’ strength and reduce their aftereffects. Learn More  Treating KCNA2-Encephalopathy: Researchers have used a drug approved for the treatment of multiple sclerosis to treat a rare form of genetic epilepsy. This type of epilepsy is caused by a mutation in the KCNA2 gene, which leads to defective potassium channels in the brain. The researchers found that the compound 4-aminopyridine (generic name fampiridine, brand name Ampyra)  was effective in reducing disease-related symptoms in 9 of 11 patients carrying this mutation. Though the drug isn’t effective for everyone with this type of epilepsy, the researchers have created a database to reference so that doctors can quickly decide whether the drug is a viable option for a person with a newly diagnosed KCNA2 gene defect. Learn More  Epilepsy Surgery and Brain Health: Epilepsy surgery may be associated with improvements in overall brain health. A study used advanced imaging techniques to determine whether surgery in patients with mesial temporal lobe epilepsy (mTLE) is associated with reduced “BrainAGE” as a sign of overall brain health. MRI analysis of brain-predicted and chronological age difference (BrainAGE) is thought to provide a surrogate marker of overall brain health; the greater the BrainAGE, the lower the overall brain health. The experiment shows that BrainAGE is greater in patients with refractory (difficult-to-treat) TLE by at least seven years compared to healthy controls and that this difference is reduced after epilepsy surgery. The researchers state that their findings are in line with other work suggesting that earlier surgery may benefit patients with refractory TLE. Learn More 

September 13, 2021

Researcher Update: September 2021

In this month's update, you'll find information on Unite to CURE Epilepsy and grant funding opportunities

September 13, 2021

CURE Epilepsy Announces 2021 Unite to CURE Epilepsy Virtual Community Fundraiser

Chicago, Illinois – CURE Epilepsy is pleased to announce our 2021 Unite to CURE Epilepsy virtual community fundraiser which will be held Friday September 17th beginning at 8pm Eastern | 5pm Pacific time. You can view the free event live by registering at CUREepilepsy.org/Unite2021. Unite to CURE Epilepsy will bring together the community and advocates from around the world to help raise funds for critically needed epilepsy research. It will feature moving stories from across the epilepsy community, promising research from leading researchers, and engaging and inspirational performances from musical stars such as Rock & Roll Hall of Fame inductee, solo artist, and member of the E Street Band and Neil Young and Crazy Horse, Nils Lofgren, and TV and film actor, and star of Broadway’s Hamilton, Miguel Cervantes. The show will also highlight a special guest appearance from 8-time James Beard Award-winning chef Rick Bayless and NBC and MSNBC medical contributor, Dr. Kavita Patel. “I am delighted to be hosting Unite to CURE Epilepsy for a second year,” said Mike Barnicle, award-winning journalist, contributor to MSNBC’s Morning Joe, and Julia’s dad. “CURE Epilepsy is an incredibly important organization to me and my family, as we too have been touched by epilepsy. Knowing that CURE Epilepsy is resolute in their commitment to finding a cure for this disease gives me hope that one day we will live in a world without epilepsy.” Beth Dean, CEO of CURE Epilepsy, added, “We’re so grateful to Mike and all the amazingly talented guests who are participating in this year’s program. Our Unite to CURE Epilepsy virtual event showcases the power of this community and the ability for research to change the outcome for those living with epilepsy. By coming together to focus our efforts and raise money, we make a difference that will allow us to find a cure for this devastating disease.” The event is free to attend. Please register to join us at CUREepilepsy.org/Unite2021. The event will air live on Friday, September 17th beginning at 8pm Eastern | 7pm Central | 6pm Mountain | 5pm Pacific. All proceeds from this event will benefit CURE Epilepsy, an organization with an unwavering commitment to funding research to find a cure for epilepsy. Since its founding more than 20 years ago, CURE Epilepsy has raised over $78 million to fund innovative research to advance our goal of no seizures and no side effects. To date CURE Epilepsy has awarded more than 270 cutting-edge research projects in 17 countries around the world with the goal of achieving our vision: a world without epilepsy. ###   Press Contact: Debby Hecht CURE Epilepsy 312.971.8443 Debby.Hecht@CUREepilepsy.org  

September 10, 2021

Anesthesia Considerations for Patients with Epilepsy: Findings of a Qualitative Study in the Palestinian Practice

Findings of this study might be used to inform anesthesiologists and decision makers in professional groups, patient advocacy groups, and healthcare authorities to benchmark and improve anesthesia care and services offered to patients with epilepsy.

September 10, 2021

Outcomes in the Treatment of Psychogenic Nonepileptic Seizures (PNES) with Cognitive Behavioral Therapy-Informed Psychotherapy

Patients treated with cognitive behavioral therapy-informed psychotherapy with a minimum of 7 sessions in 3 months did not have significant improvement.

September 10, 2021

Can Medical Marijuana Effectively Treat Childhood Epilepsy?

They stress that unlicensed cannabis-based medicinal products should not circumvent usual regulatory requirements before being prescribed.

September 10, 2021

Efficacy and Safety of Ketogenic Dietary Therapies in Infancy. A Single-Center Experience in 42 Infants Less Than Two Years of Age

Ketogenic dietary therapies are useful and effective treatments in infancy. Side effects are frequent but mild and easy to manage.

1 2 148


    Join our email list for the
    latest epilepsy research news,
    discoveries, and more.